Nature Communications · 2014 · 55 citations · 35 references
MedicineNeurosciencePharmacologyIon Channel BiophysicsMolecular PharmacologyNeuropharmacologyIon Channel PharmacologyIon Channel PhysiologyIon ChannelsNeuroprotectionCalcium Channel FunctionCalcium Channel ModulatorsCalcium Channel PharmacologyCalcium Channel PhysiologyChannelsL-type Calcium CurrentNeuroprotective MechanismsVoltage-gated Calcium Channels
Cav1.2 and Cav1.3 are the main L-type Ca2+ channel subtypes in the brain. Cav1.3 channels have recently been implicated in the pathogenesis of Parkinson’s disease. Therefore, Cav1.3-selective blockers are developed as promising neuroprotective drugs. We studied the pharmacological properties of a pyrimidine-2,4,6-trione derivative (1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione, Cp8) recently reported as the first highly selective Cav1.3 blocker. Here we show, in contrast to this previous study, that Cp8 reproducibly increases inward Ca2+ currents of Cav1.3 and Cav1.2 channels expressed in tsA-201 cells by slowing activation, inactivation and enhancement of tail currents. Similar effects are also observed for native Cav1.3 and Cav1.2 channels in mouse chromaffin cells, while non-L-type currents are unaffected. Evidence for a weak and non-selective inhibition of Cav1.3 and Cav1.2 currents is only observed in a minority of cells using Ba2+ as charge carrier. Therefore, our data identify pyrimidine-2,4,6-triones as Ca2+ channel activators. Selective inhibitors of the L-type Ca2+ channel Cav1.3 are being developed as neuroprotective drugs. Here, Ortner et al. assess the pharmacological properties of a recently reported, selective Cav1.3 blocker and show that this agent is a Ca2+channel activator.
35
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
C. Savio Chan, Jaime N. Guzmán, Ema Ilijić et al. · Nature · 2007 · 906 citations